Health care stocks gained late Monday afternoon with the NYSE Health Care Index climbing 1.1% and the Health Care Select Sector SPDR Fund (XLV) rising 0.9%.
The iShares Biotechnology ETF (IBB) was up 0.1%.
In corporate news, Amneal Pharmaceuticals (AMRX) shares jumped 7% after JPMorgan upgraded the stock to overweight from neutral and raised its price target to $12 from $9.
PepGen (PEPG) shares surged 66% after it reported initial positive data from a phase 1 trial investigating PGN-EDODM1 in myotonic dystrophy type 1.
Amgen (AMGN) will invest an initial $200 million this year in its new technology center in southern India, Reuters reported, citing Chief Executive Robert Bradway. Amgen confirmed the plans in a statement sent to MT Newswires, saying that the investment would back the acceleration of its digital capabilities through AI and data science. Amgen shares rose 2%.
Invivyd (IVVD) dropped 31% after the firm said the US Food and Drug Administration rejected its request to expand the existing emergency use authorization for Pemgarda to include treatment of mild-to-moderate COVID-19 in immunocompromised persons.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.